MMT plans on initiating one or more clinical
trials to evaluate the effectiveness of two particular
in the treatment of Preclinical Alzheimer’s disease. These medications are approved
by FDA for other indications and have shown promise in preventing the progression of Preclinical
Alzheimer’s disease and / or of Alzheimer’s disease.
Please return to the MMT website periodically to check on the status of these pending studies.